RNA/NN
Mapping/NN
of/IN
Mutant/JJ
Myotonic/JJ
Dystrophy/NN
Protein/NN
Kinase/NN
3/CD
’/NN
-Untranslated/JJ
Region/NN
Transcripts/NNS
./.
====================
Myotonic/JJ
dystrophy/NN
type/NN
1/CD
(/(
DM1/NN
)/)
,/,
which/WDT
is/VBZ
a/DT
dominantly/RB
inherited/VBN
neurodegenerative/JJ
disorder/NN
,/,
results/VBZ
from/IN
a/DT
CTG/NN
trinucleotide/NN
repeat/NN
expansion/NN
in/IN
the/DT
3/CD
’/NN
untranslated/JJ
region/NN
(/(
3/CD
’/NN
-UTR/NN
)/)
of/IN
the/DT
myotonic/JJ
dystrophy/NN
protein/NN
kinase/NN
(/(
DMPK/NN
)/)
gene/NN
./.
====================
Retention/NN
of/IN
mutant/JJ
DMPK/NN
(/(
mDMPK/NN
)/)
transcripts/NNS
in/IN
the/DT
nuclei/NNS
of/IN
affected/VBN
cells/NNS
has/VBZ
been/VBN
known/VBN
to/TO
be/VB
the/DT
main/JJ
cause/JJ
of/IN
pathogenesis/NN
of/IN
the/DT
disease/NN
./.
====================
Thus/RB
,/,
reducing/VBG
the/DT
RNA/NN
toxicity/NN
through/IN
elimination/NN
of/IN
the/DT
mutant/JJ
RNA/NN
has/VBZ
been/VBN
suggested/VBN
as/IN
one/CD
therapeutic/JJ
strategy/NN
against/IN
DM1/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
suggested/VBD
RNA/NN
replacement/NN
with/IN
a/DT
trans-splicing/JJ
ribozyme/NN
as/IN
an/DT
alternate/JJ
genetic/JJ
therapeutic/JJ
approach/NN
for/IN
amelioration/NN
of/IN
DM1/NN
./.
====================
To/TO
this/DT
end/NN
,/,
we/PRP
identified/VBD
the/DT
regions/NNS
of/IN
mDMPK/NN
3/CD
’/NN
-UTR/NN
RNA/NN
that/DT
were/VBD
accessible/JJ
to/TO
ribozymes/NNS
by/IN
using/VBG
an/DT
RNA/NN
mapping/NN
strategy/NN
based/VBN
on/IN
a/DT
trans/JJ
splicing/NN
ribozyme/NN
library/NN
./.
====================
We/PRP
found/VBD
that/IN
particularly/RB
accessible/JJ
sites/NNS
were/VBD
present/JJ
not/RB
only/RB
upstream/RB
but/CC
also/RB
downstream/RB
of/IN
the/DT
expanded/VBN
repeat/NN
sequence/NN
./.
====================
Repair/NN
or/CC
replacement/JJ
of/IN
the/DT
mDMPK/NN
transcript/NN
with/IN
the/DT
specific/JJ
ribozyme/NN
will/MD
be/VB
useful/JJ
for/IN
DM1/NN
treatment/NN
through/IN
reduction/NN
of/IN
toxic/JJ
mutant/JJ
transcripts/NNS
and/CC
simultaneously/RB
restore/VB
wild-type/JJ
DMPK/NN
or/CC
release/NN
nucleusentrapped/JJ
mDMPK/NN
transcripts/NNS
to/TO
the/DT
cytoplasm/NN
./.
====================
DM1/NN
is/VBZ
an/DT
autosomal/JJ
dominant/JJ
genetic/JJ
and/CC
the/DT
most/JJS
common/JJ
neuromuscular/JJ
disease/NN
in/IN
adults/NNS
,/,
affecting/VBG
approximately/RB
5/CD
to/TO
20/CD
out/RP
of/IN
100,000/CD
among/IN
the/DT
worldwide/NN
population/NN
including/VBG
Asians/NNS
(/(
Harper/JJ
,/,
2001/CD
)/)
./.
====================
The/DT
DM/NN
mutation/NN
is/VBZ
a/DT
CTG/NN
trinucleotide/NN
expansion/NN
in/IN
the/DT
3/CD
’/NN
-UTR/NN
of/IN
the/DT
DMPK/NN
gene/NN
on/IN
chromosome/NN
19q/NN
(/(
Brook/JJ
et/FW
al./FW
,/,
1992/CD
)/)
./.
====================
The/DT
severity/NN
of/IN
disease/NN
is/VBZ
proportional/JJ
to/TO
the/DT
number/NN
of/IN
the/DT
expanded/VBN
CTG/NN
repeats/NNS
./.
====================
The/DT
number/NN
of/IN
repeats/NNS
is/VBZ
in/IN
the/DT
range/NN
of/IN
535/CD
in/IN
the/DT
normal/JJ
population/NN
,/,
and/CC
DM/NN
alleles/NNS
harbor/VBP
more/RBR
than/IN
50/CD
and/CC
up/IN
to/TO
several/JJ
thousand/DT
repeats/NNS
in/IN
DM1/NN
patients/NNS
./.
====================
The/DT
pathogenesis/NN
of/IN
DM1/NN
is/VBZ
directly/RB
mediated/VBN
by/IN
a/DT
toxic/JJ
mDMPK/NN
RNA/NN
that/DT
is/VBZ
entrapped/VBN
in/IN
the/DT
affected/VBN
cell/NN
nucleus/NN
./.
====================
A/DT
number/NN
of/IN
pieces/NNS
of/IN
evidence/NN
suggest/VBP
that/IN
pleiotropic/JJ
effects/NNS
of/IN
aberrant/JJ
interactions/NNS
between/IN
the/DT
mDMPK/NN
transcripts/NNS
that/WDT
are/VBP
retained/VBN
in/IN
the/DT
nucleus/NN
and/CC
RNA/NN
binding/NN
proteins/NNS
,/,
such/JJ
as/IN
muscleblindlike/JJ
1/CD
,/,
change/NN
the/DT
metabolism/NN
of/IN
target/NN
mRNAs/NNS
,/,
including/VBG
splicing/NN
(/(
Wheeler/NNP
,/,
2008/CD
)/)
./.
====================
Additively/RB
,/,
decreased/VBD
DMPK/NN
protein/NN
levels/NNS
in/IN
DM1/NN
patients/NNS
due/IN
to/TO
loss/NN
of/IN
cytoplasmlocalized/JJ
mRNA/NN
for/IN
translation/NN
could/MD
cause/VB
physiological/JJ
and/CC
functional/JJ
alterations/NNS
in/IN
phosphorylation/NN
of/IN
target/NN
proteins/NNS
,/,
including/VBG
CUGbinding/JJ
protein/NN
1/CD
,/,
and/CC
hence/RB
has/VBZ
been/VBN
suggested/VBN
as/IN
a/DT
contributor/NN
to/TO
the/DT
pathology/NN
of/IN
the/DT
disease/NN
(/(
Kaliman/JJ
and/CC
Llagostera/NN
,/,
2008/CD
)/)
./.
====================
There/EX
is/VBZ
no/DT
cure/JJ
for/IN
DM/NN
yet/RB
./.
====================
However/RB
,/,
several/JJ
approaches/NNS
to/TO
reduce/VB
the/DT
mutant/JJ
RNAmediated/JJ
toxicity/NN
through/IN
elimination/NN
of/IN
nucleustrapped/JJ
toxic/JJ
mDMPK/NN
transcripts/NNS
have/VBP
been/VBN
proposed/VBN
as/IN
specific/JJ
therapies/NNS
for/IN
reversal/JJ
of/IN
the/DT
disease/NN
phenotype/NN
./.
====================
They/PRP
include/VBP
approaches/NNS
with/IN
antisense/JJ
,/,
small/JJ
catalytic/JJ
RNA/NN
,/,
or/CC
siRNA/JJ
,/,
which/WDT
can/MD
reduce/VB
the/DT
level/NN
of/IN
mDMPK/NN
RNA/NN
by/IN
directly/RB
targeting/VBG
the/DT
expanded/VBN
CUG/NN
repeats/NNS
of/IN
the/DT
mDMPK/NN
transcript/NN
(/(
Furling/JJ
et/FW
al./FW
,/,
2003/CD
;/:
Krol/NN
et/FW
al./FW
,/,
2007/CD
;/:
Langlois/NNP
et/FW
al./FW
,/,
2003/CD
;/:
Mahadevan/NNP
et/FW
al./FW
,/,
2006/CD
)/)
./.
====================
However/RB
,/,
high/JJ
specificity/NN
for/IN
degradation/NN
of/IN
the/DT
mutant/JJ
alleles/NNS
,/,
nontoxicity/NN
,/,
and/CC
lack/NN
of/IN
offtarget/JJ
effects/NNS
will/MD
be/VB
required/VBN
to/TO
minimize/VB
nonspecific/JJ
reduction/NN
of/IN
the/DT
normal/JJ
allele/NN
and/CC
cellular/JJ
toxicity/NN
./.
====================
RNA/NN
repair/NN
or/CC
RNA/NN
replacement/NN
has/VBZ
been/VBN
described/VBN
as/IN
a/DT
new/JJ
approach/NN
to/TO
human/JJ
gene/NN
therapy/NN
against/IN
genetic/JJ
disorders/NNS
,/,
which/WDT
relies/VBZ
on/IN
the/DT
Tetrahymena/NN
group/NN
Ibased/VBD
transsplicing/VBG
ribozyme/NN
(/(
Sullenger/NN
and/CC
Gilboa/NN
,/,
2002/CD
)/)
./.
====================
This/DT
ribozyme/NN
could/MD
cleave/VB
a/DT
target/NN
5/CD
’/NN
exon/NN
RNA/NN
and/CC
transligate/VBP
an/DT
exon/NN
that/DT
is/VBZ
tagged/VBN
at/IN
its/PRP$
3/CD
’/NN
end/NN
onto/IN
the/DT
cleaved/JJ
target/NN
RNA/NN
both/CC
in/IN
vitro/FW
and/CC
in/IN
bacteria/NNS
and/CC
mammalian/JJ
cells/NNS
(/(
Been/NNP
and/CC
Cech/JJ
,/,
1986/CD
;/:
Sullenger/NNP
and/CC
Cech/JJ
,/,
1994/CD
;/:
Jones/NNS
et/FW
al./FW
,/,
2006/CD
)/)
./.
====================
Therefore/RB
,/,
the/DT
transsplicing/VBG
ribozyme/NN
can/MD
reduce/VB
the/DT
level/NN
of/IN
a/DT
specific/JJ
target/NN
RNA/NN
and/CC
simultaneously/RB
induce/VBP
transgene/NN
activity/NN
specifically/RB
in/IN
the/DT
target/NN
RNA/NN
expressing/VBG
cells/NNS
./.
====================
Indeed/RB
,/,
transsplicing/VBG
ribozymes/NNS
have/VBP
been/VBN
successfully/RB
developed/VBD
to/TO
replace/VB
mutant/JJ
transcripts/NNS
that/WDT
are/VBP
associated/VBN
with/IN
several/JJ
human/JJ
genetically/RB
inherited/VBN
diseases/NNS
,/,
including/VBG
DM1/NN
(/(
Lan/JJ
et/FW
al./FW
,/,
1998/CD
;/:
Phylactou/NNP
et/FW
al/JJ
./.
====================
1998/CD
;/:
Rogers/NNS
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
Moreover/RB
,/,
we/PRP
have/VBP
shown/VBN
that/IN
trans-splicing/VBG
ribozyme/NN
targeting/VBG
and/CC
replacing/VBG
the/DT
human/JJ
telomerase/NN
reverse/JJ
transcriptase/NN
(/(
hTERT/NN
)/)
RNA/NN
could/MD
specifically/RB
and/CC
efficiently/RB
regress/RB
human/JJ
tumors/NNS
not/RB
only/RB
in/IN
cell/NN
cultures/NNS
but/CC
also/RB
in/IN
animals/NNS
without/IN
any/DT
toxicity/NN
in/IN
normal/JJ
tissues/NNS
or/CC
any/DT
off-target/RB
splicing/NN
effects/NNS
(/(
Hong/JJ
et/FW
al./FW
,/,
2008/CD
;/:
Jeong/NNP
et/FW
al./FW
,/,
2008/CD
;/:
Kwon/NNP
et/FW
al./FW
,/,
2005/CD
;/:
Song/JJ
and/CC
Lee/NNP
,/,
2008/CD
;/:
Song/JJ
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
Thus/RB
,/,
a/DT
trans-splicing/JJ
ribozyme/NN
that/DT
can/MD
repair/VB
toxic/JJ
mDMPK/NN
RNA/NN
with/IN
the/DT
wild-type/JJ
one/CD
or/CC
replace/JJ
the/DT
nucleus-entrapped/JJ
mutant/JJ
transcripts/NNS
with/IN
RNA/NN
that/DT
can/MD
be/VB
released/VBN
into/IN
the/DT
cytoplasm/NN
would/MD
be/VB
a/DT
potential/JJ
tool/NN
for/IN
DM1/NN
treatment/NN
./.
====================
To/TO
this/DT
end/NN
,/,
we/PRP
have/VBP
developed/VBN
mDMPK/NN
3/CD
’/NN
-UTR-specific/JJ
transsplicing/VBG
ribozymes/NNS
by/IN
utilizing/VBG
an/DT
RNA/NN
mapping/NN
procedure/NN
that/DT
identifies/VBZ
the/DT
most/JJS
accessible/JJ
ribozyme/NN
sites/NNS
./.
====================
Any/DT
uridine/NN
(/(
U/NNP
)/)
residue/NN
in/IN
a/DT
target/NN
RNA/NN
can/MD
be/VB
targeted/VBN
for/IN
splicing/NN
by/IN
the/DT
trans-splicing/VBG
ribozyme/NN
through/IN
alteration/NN
of/IN
the/DT
internal/JJ
guide/NN
sequence/NN
(/(
IGS/NN
)/)
,/,
which/WDT
is/VBZ
the/DT
5/CD
’/NN
-exon/JJ
binding/VBG
site/NN
of/IN
the/DT
ribozyme/NN
,/,
to/TO
make/VB
it/PRP
complementary/JJ
to/TO
the/DT
target/NN
sequence/NN
(/(
Long/JJ
et/FW
al./FW
,/,
2003/CD
;/:
Sullenger/NNP
,/,
1995/CD
)/)
./.
====================
However/RB
,/,
the/DT
ribozyme/NN
can/MD
actually/RB
access/RB
only/RB
a/DT
limited/JJ
number/NN
of/IN
uridines/NNS
on/IN
the/DT
target/NN
RNA/NN
due/JJ
to/TO
complicated/VBN
tertiary/JJ
structure/NN
formation/NN
of/IN
the/DT
substrate/NN
RNA/NN
(/(
Lan/JJ
et/FW
al./FW
,/,
2000/CD
)/)
./.
====================
To/TO
develop/VB
most/JJS
potential/JJ
mDMPK/NN
3/CD
’/NN
-UTRspecific/JJ
ribozymes/NNS
,/,
therefore/RB
,/,
identification/NN
of/IN
the/DT
regions/NNS
of/IN
the/DT
target/NN
transcript/NN
that/WDT
are/VBP
accessible/JJ
to/TO
ribozymes/NNS
should/MD
be/VB
performed/VBN
first/JJ
./.
====================
To/TO
this/DT
end/NN
,/,
we/PRP
employed/VBD
an/DT
RNA/NN
mapping/NN
strategy/NN
based/VBN
on/IN
RNA/NN
tagging/VBG
(/(
Jones/NNS
et/FW
al.,1996/FW
)/)
and/CC
a/DT
trans/JJ
splicing/NN
ribozyme/NN
library/NN
,/,
which/WDT
has/VBZ
been/VBN
described/VBN
in/IN
detail/NN
elsewhere/RB
(/(
Fig/NN
./.
====================
1/CD
)/)
(/(
Lan/JJ
et/FW
al./FW
,/,
1998/CD
;/:
Lan/NNP
et/FW
al./FW
,/,
2000/CD
;/:
Kwon/NN
et/FW
al./FW
,/,
2005/CD
;/:
Ryu/NNP
et/FW
al./FW
,/,
2003/CD
;/:
Song/JJ
and/CC
Lee/NNP
,/,
2007/CD
)/)
./.
====================
We/PRP
constructed/VBD
the/DT
GN5/NN
ribozyme/NN
library/NN
,/,
which/WDT
is/VBZ
based/VBN
on/IN
the/DT
Tetrahymena/NN
group/NN
I/NN
intron/NN
and/CC
contains/VBZ
a/DT
randomized/JJ
IGS/NN
./.
====================
Ribozymes/NNS
in/IN
the/DT
GN5/NN
library/NN
can/MD
bind/VB
to/TO
the/DT
substrate/NN
RNA/NN
,/,
cleave/VBP
at/IN
any/DT
accessible/JJ
U/NNP
residue/NN
,/,
and/CC
transfer/NN
a/DT
3/CD
’/NN
exon/NN
that/DT
is/VBZ
tagged/VBN
onto/IN
the/DT
ribozyme/NN
to/TO
the/DT
end/NN
of/IN
the/DT
cleaved/JJ
5/CD
’/NN
target/NN
product/NN
./.
====================
We/PRP
used/VBD
a/DT
portion/NN
of/IN
the/DT
lacZ/NN
gene/NN
as/IN
a/DT
3/CD
’/NN
exon/NN
molecular/JJ
tag/NN
in/IN
the/DT
GN5/NN
library/NN
./.
====================
mDMPK/RB
3/CD
’/NN
UTR/NN
RNA/NN
was/VBD
synthesized/VBN
using/VBG
in/IN
vitro/FW
transcription/NN
of/IN
PCRamplified/JJ
vector/NN
encoding/VBG
the/DT
mDMPK/NN
3/CD
’/NN
UTR/NN
gene/NN
with/IN
200/CD
CTG/NN
repeats/NNS
(/(
kindly/RB
supplied/VBD
by/IN
Dr./NNP
Leonidas/NNP
Phylactou/NN
at/IN
the/DT
Cyprus/NN
Institute/JJ
of/IN
Neurology/NN
and/CC
Genetics/NNS
)/)
./.
====================
In/IN
order/NN
to/TO
map/VB
the/DT
mDMPK/NN
3/CD
’/NN
UTR/NN
RNA/NN
,/,
GN5/NNP
library/NN
RNA/NN
(/(
10/CD
nM/NN
)/)
was/VBD
incubated/VBN
at/IN
37°C/NN
for/IN
3/CD
hrs/NNS
under/IN
splicing/NN
conditions/NNS
(/(
50/CD
mM/NN
HEPES/NN
,/,
pH/NN
7.0/CD
,/,
150/CD
mM/NN
NaCl/NN
,/,
5/CD
mM/NN
MgCl2/NN
)/)
in/IN
the/DT
presence/NN
of/IN
guanosine/NN
(/(
200/CD
μM/NN
)/)
and/CC
in/IN
vitro-generated/JJ
target/NN
RNA/NN
(/(
100/CD
nM/NN
)/)
./.
====================
The/DT
trans-splicing/VBG
reaction/NN
products/NNS
were/VBD
then/RB
reversetranscribed/VBD
at/IN
37°C/NN
for/IN
30/CD
min/NN
in/IN
the/DT
presence/NN
of/IN
argininamide/NN
(/(
10/CD
mM/NN
)/)
with/IN
a/DT
3/CD
’/NN
primer/NN
that/DT
was/VBD
specific/JJ
for/IN
the/DT
ribozyme/NN
’/CD
s/NNS
3/CD
’/NN
-exon/JJ
lacZ/NN
sequence/NN
(/(
5/CD
’/NN
-ATGTGCTGCAAG/NN
GCGATT-3/NN
’/CD
)/)
(/(
Jones/NNS
et/FW
al/JJ
./.
====================
1996/CD
)/)
./.
====================
Produced/JJ
cDNAs/NNS
were/VBD
amplified/VBN
by/IN
PCR/NN
for/IN
30/CD
cycles/NNS
using/VBG
the/DT
same/JJ
3/CD
’/NN
primer/NN
and/CC
a/DT
5/CD
’/NN
primer/NN
that/DT
was/VBD
specific/JJ
for/IN
the/DT
5/CD
’/NN
end/NN
of/IN
the/DT
target/NN
RNA/NN
(/(
5/CD
’/NN
-ACCCTAGAACTGTCTTCGACTCC3/NN
’/CD
)/)
or/CC
downstream/JJ
region/NN
of/IN
the/DT
expanded/VBN
CTG/NN
sequence/NN
(/(
5/CD
’/NN
-GGAATTCGGGGGATCACAGACCAT3/NN
’/CD
)/)
./.
====================
The/DT
amplified/VBN
trans-/JJ
splicing/NN
products/NNS
were/VBD
then/RB
cloned/VBN
into/IN
the/DT
pUC19/NN
vector/NN
,/,
and/CC
sequences/NNS
of/IN
several/JJ
clones/NNS
were/VBD
determined/VBN
./.
====================
’/RB
When/WRB
we/PRP
analyzed/VBD
sequences/NNS
of/IN
the/DT
splicing/NN
junction/NN
sites/NNS
of/IN
the/DT
trans-spliced/JJ
products/NNS
amplified/VBN
with/IN
the/DT
5/CD
’/NN
-end/NN
of/IN
the/DT
target/NN
RNA/NN
as/IN
the/DT
5/CD
’/NN
primer/NN
,/,
several/JJ
uridines/NNS
,/,
only/RB
in/IN
the/DT
upstream/JJ
of/IN
the/DT
expanded/VBN
trinucleotide/NN
repeat/NN
sequence/NN
,/,
appeared/VBD
to/TO
be/VB
particularly/RB
accessible/JJ
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
Long/JJ
hairpin/NN
structures/NNS
of/IN
the/DT
expanded/VBN
trinucleotide/NN
repeat/NN
might/MD
hamper/NN
PCR/NN
amplification/NN
of/IN
transspliced/JJ
products/NNS
that/IN
result/VBP
from/IN
the/DT
splicing/NN
reaction/NN
with/IN
U/NNP
residues/NNS
downstream/JJ
of/IN
the/DT
trinucleotide/NN
repeat/NN
sequence/NN
./.
====================
To/TO
identify/VB
accessible/JJ
U/NNP
residues/NNS
in/IN
the/DT
target/NN
RNA/NN
that/DT
were/VBD
present/JJ
downstream/RB
of/IN
the/DT
trinucleotide/NN
repeat/NN
,/,
we/PRP
also/RB
amplified/VBD
transsplicing/VBG
products/NNS
with/IN
the/DT
5/CD
’/NN
primer/NN
that/DT
was/VBD
specific/JJ
for/IN
right/JJ
downstream/JJ
part/NN
of/IN
the/DT
trinucleotide/NN
repeat/NN
sequence/NN
./.
====================
Then/RB
,/,
several/JJ
uridines/NNS
downstream/JJ
of/IN
the/DT
expanded/VBN
CUG/NN
repeat/NN
sequence/NN
were/VBD
also/RB
shown/VBN
to/TO
be/VB
particularly/RB
accessible/JJ
./.
====================
In/IN
conclusion/NN
,/,
the/DT
most/JJS
accessible/JJ
site/NN
upstream/RB
of/IN
the/DT
CUG/NN
repeat/NN
sequence/NN
was/VBD
located/JJ
in/IN
the/DT
uridine/NN
at/IN
position/NN
99/CD
of/IN
the/DT
mDMPK/NN
3/CD
’/NN
UTR/NN
RNA/NN
./.
====================
In/IN
addition/NN
,/,
the/DT
uridine/NN
at/IN
position/NN
854/CD
of/IN
the/DT
target/NN
RNA/NN
was/VBD
the/DT
most/JJS
accessible/JJ
site/NN
that/WDT
was/VBD
present/JJ
downstream/JJ
of/IN
the/DT
CUG/NN
repeat/NN
./.
====================
Interestingly/RB
,/,
most/JJS
of/IN
the/DT
accessible/JJ
sites/NNS
,/,
including/VBG
positions/NNS
99/CD
and/CC
854/CD
,/,
which/WDT
were/VBD
identified/VBN
using/VBG
this/DT
mapping/VBG
method/NN
,/,
were/VBD
generally/RB
present/JJ
in/IN
the/DT
loop/NN
or/CC
bulge/JJ
region/NN
of/IN
the/DT
RNA/NN
’/NN
s/NNS
secondary/JJ
structure/NN
,/,
as/IN
predicted/VBN
by/IN
a/DT
computer/NN
program/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
In/IN
contrast/NN
,/,
no/DT
accessible/JJ
sites/NNS
were/VBD
found/VBN
in/IN
the/DT
long/JJ
hairpinformed/VBD
CUG/NN
repeat/NN
region/NN
./.
====================
In/IN
previous/JJ
studies/NNS
,/,
we/PRP
showed/VBD
that/IN
the/DT
relative/JJ
transsplicing/VBG
reaction/NN
efficacy/NN
at/IN
different/JJ
sites/NNS
in/IN
a/DT
target/NN
RNA/NN
in/IN
cells/NNS
and/CC
in/IN
vitro/FW
was/VBD
closely/RB
associated/VBN
with/IN
the/DT
predicted/VBN
accessibility/NN
determined/VBN
by/IN
mapping/VBG
results/VBZ
(/(
Ryu/NNP
et/FW
al./FW
,/,
2003/CD
;/:
Ryu/NNP
and/CC
Lee/NNP
,/,
2004/CD
;/:
Kwon/NNP
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
Therefore/RB
,/,
the/DT
ribozymes/NNS
that/DT
target/NN
the/DT
ac/NN
cessible/JJ
sites/NNS
identified/VBD
here/RB
are/VBP
anticipated/JJ
to/TO
be/VB
more/RBR
active/JJ
than/IN
those/DT
that/DT
target/NN
other/JJ
sites/NNS
./.
====================
A/DT
specific/JJ
ribozyme/NN
that/DT
targeted/VBN
position/NN
99/CD
or/CC
854/CD
of/IN
the/DT
mDMPK/NN
3/CD
’/NN
-UTR/NN
RNA/NN
(/(
Rib99/NN
or/CC
Rib854/NN
,/,
respectively/RB
)/)
was/VBD
constructed/VBN
by/IN
in/FW
vitro/FW
transcription/NN
of/IN
cDNA/NN
template/NN
./.
====================
We/PRP
made/VBD
cDNA/NN
template/NN
by/IN
PCR/NN
of/IN
the/DT
pT7L-21/NN
plasmid/NN
with/IN
a/DT
5/CD
’/NN
primer/NN
that/IN
contained/VBD
the/DT
T7/NN
promoter/NN
and/CC
each/DT
ribozyme/NN
’/CD
s/NNS
IGS/NN
,/,
and/CC
a/DT
3/CD
’/NN
primer/NN
that/IN
was/VBD
specific/JJ
for/IN
the/DT
3/CD
’/NN
-exon/JJ
sequence/NN
,/,
as/IN
described/VBN
(/(
Sullenger/NNP
and/CC
Cech/JJ
,/,
1994/CD
;/:
Jones/NNS
et/FW
al./FW
,/,
1996/CD
)/)
./.
====================
The/DT
pT7L-21/NN
plasmid/NN
encodes/VBZ
a/DT
slightly/RB
shortened/JJ
version/NN
of/IN
the/DT
native/JJ
group/NN
I/NN
intron/NN
from/IN
Tetrahymena/NN
./.
====================
The/DT
IGS/NN
of/IN
the/DT
L-21/NN
trans-splicing/VBG
ribozyme/NN
(/(
5'GGAGGG3/NN
'/``
)/)
was/VBD
exchanged/VBN
with/IN
5'-GGCGGT-3/NN
'/``
in/IN
Rib99/NN
or/CC
with/IN
5/CD
’/NN
-GGAAAG-3/NN
’/CD
in/IN
Rib854/NN
./.
====================
The/DT
specific/JJ
ribozyme/NN
(/(
100/CD
nM/NN
)/)
was/VBD
then/RB
incubated/VBN
with/IN
the/DT
substrate/NN
RNA/NN
(/(
10/CD
nM/NN
)/)
under/IN
splicing/NN
conditions/NNS
./.
====================
RT-PCR/NN
analyses/NNS
were/VBD
performed/VBN
using/VBG
a/DT
3/CD
'/``
primer/NN
that/DT
was/VBD
specific/JJ
for/IN
the/DT
3/CD
'/``
exon/NN
tag/NN
sequence/NN
and/CC
a/DT
5/CD
'/``
primer/NN
that/DT
was/VBD
specific/JJ
for/IN
the/DT
mDMPK/NN
3/CD
’/NN
-UTR/NN
RNA/NN
./.
====================
The/DT
amplified/VBN
fragment/NN
could/MD
be/VB
seen/VBN
at/IN
the/DT
expected/VBN
size/NN
of/IN
197/CD
bp/NN
or/CC
130/CD
bp/NN
when/WRB
incubating/VBG
the/DT
target/NN
RNA/NN
with/IN
Rib99/NN
or/CC
Rib854/NN
,/,
respectively/RB
(/(
data/NNS
not/RB
shown/VBN
)/)
./.
====================
Sequence/NN
analyses/NNS
of/IN
the/DT
amplified/VBN
trans-spliced/VBN
products/NNS
revealed/VBD
that/IN
both/CC
Rib99/NN
(/(
targeting/VBG
the/DT
upstream/JJ
region/NN
of/IN
the/DT
expanded/VBN
CUG/NN
repeat/NN
)/)
and/CC
Rib854/NN
(/(
targeting/VBG
the/DT
downstream/JJ
site/NN
of/IN
the/DT
expanded/VBN
CUG/NN
repeat/NN
)/)
accurately/RB
employed/VBN
the/DT
trans-splicing/VBG
reaction/NN
of/IN
their/PRP$
3'-exon/JJ
tag/NN
onto/IN
the/DT
target/NN
RNA/NN
at/IN
the/DT
predicted/VBN
reaction/NN
site/NN
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
These/DT
studies/NNS
indicate/VBP
that/IN
specific/JJ
ribozyme/NN
targeting/VBG
of/IN
predicted/VBN
accessible/JJ
sites/NNS
can/MD
replace/VB
mDMPK/NN
3/CD
’/NN
UTR/NN
RNA/NN
with/IN
a/DT
3'-exon/JJ
that/DT
is/VBZ
tagged/VBN
at/IN
the/DT
3'end/NN
of/IN
the/DT
ribozyme/NN
with/IN
high/JJ
fidelity/NN
through/IN
targeted/VBN
transsplicing/VBG
./.
====================
Recently/RB
,/,
several/JJ
gene/NN
therapy/NN
protocols/NNS
,/,
based/VBN
on/IN
inhibitory/JJ
RNA/NN
or/CC
short/JJ
oligonucleotides/NNS
that/IN
target/NN
the/DT
toxic/JJ
mDMPK/NN
transcript/NN
,/,
have/VBP
been/VBN
described/VBN
for/IN
DM1/NN
therapy/NN
(/(
Wheeler/NNP
,/,
2008/CD
)/)
./.
====================
For/IN
the/DT
successful/JJ
application/NN
of/IN
the/DT
RNA-/NN
or/CC
oligonucleotide-mediated/JJ
strategies/NNS
to/TO
clinical/JJ
DM1/NN
treatment/NN
,/,
specificity/NN
,/,
safety/NN
,/,
and/CC
efficacy/NN
,/,
in/IN
addition/NN
to/TO
delivery/NN
issues/NNS
,/,
are/VBP
important/JJ
criteria/NNS
to/TO
be/VB
considered/VBN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
developed/VBD
transsplicing/VBG
ribozymes/NNS
that/DT
can/MD
potentially/RB
repair/NN
the/DT
mutant/JJ
DMPK/NN
transcript/NN
with/IN
the/DT
wild-type/JJ
one/CD
or/CC
replace/NN
the/DT
mutant/JJ
RNA/NN
with/IN
a/DT
therapeutically/RB
relevant/JJ
transcript/NN
./.
====================
In/IN
previous/JJ
studies/NNS
,/,
we/PRP
have/VBP
shown/VBN
that/IN
hTERTspecific/JJ
trans-splicing/VBG
ribozymes/NNS
could/MD
specifically/RB
and/CC
effectively/RB
target/NN
and/CC
replace/RB
the/DT
hTERT/NN
RNA/NN
in/IN
vivo/FW
as/IN
well/RB
as/IN
in/IN
tumor/NN
cells/NNS
without/IN
toxic/JJ
effects/NNS
on/IN
normal/JJ
tissues/NNS
and/CC
without/IN
nonspecific/JJ
off-target/RB
splicing/NN
to/TO
other/JJ
RNAs/NNS
besides/VBZ
the/DT
target/NN
transcript/NN
(/(
Hong/JJ
et/FW
al./FW
,/,
2008/CD
;/:
Jeong/NNP
et/FW
al./FW
,/,
2008/CD
;/:
Song/JJ
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
The/DT
transsplicing/VBG
ribozyme/NN
that/DT
targets/VBZ
upstream/RB
of/IN
the/DT
expanded/VBN
CUG/NN
repeats/NNS
(/(
Rib99/NN
)/)
that/WDT
was/VBD
developed/VBN
in/IN
this/DT
study/NN
could/MD
be/VB
used/VBN
as/IN
a/DT
repair/NN
tool/NN
to/TO
restore/VB
the/DT
wildtype/JJ
DMPK/NN
protein/NN
./.
====================
A/DT
major/JJ
advantage/NN
of/IN
the/DT
RNA/NN
repair/NN
approach/NN
with/IN
a/DT
transsplicing/JJ
ribozyme/NN
for/IN
DM1/NN
therapy/NN
is/VBZ
that/DT
the/DT
ribozyme/NN
could/MD
restore/VB
and/CC
maintain/VBP
the/DT
regulated/VBN
expression/NN
of/IN
normal/JJ
DMPK/NN
protein/NN
and/CC
that/IN
it/PRP
could/MD
simultaneously/RB
reduce/VBP
the/DT
production/NN
of/IN
toxic/JJ
mutant/JJ
DMPK/NN
RNA/NN
./.
====================
However/RB
,/,
targeting/VBG
sites/NNS
in/IN
the/DT
mDMPK/NN
3/CD
’/NN
UTR/NN
are/VBP
also/RB
present/JJ
in/IN
the/DT
wildtype/JJ
DMPK/NN
RNA/NN
./.
====================
Therefore/RB
,/,
one/CD
limitation/NN
of/IN
the/DT
RNA/NN
repair/NN
approach/NN
is/VBZ
the/DT
possibility/NN
of/IN
targeting/VBG
normal/JJ
alleles/NNS
./.
====================
Although/IN
targeting/VBG
and/CC
replacing/VBG
normal/JJ
DMPK/NN
RNA/NN
with/IN
a/DT
trans/JJ
splicing/NN
ribozyme/NN
will/MD
not/RB
lead/VB
to/TO
reduction/NN
of/IN
normal/JJ
protein/NN
,/,
the/DT
efficacy/NN
of/IN
repair/NN
of/IN
mutant/JJ
transcript/NN
can/MD
decrease/VB
./.
====================
Therefore/RB
,/,
highefficiency/NN
targeting/VBG
to/TO
the/DT
target/NN
RNA/NN
will/MD
be/VB
a/DT
critical/JJ
factor/NN
for/IN
a/DT
successful/JJ
therapeutic/JJ
outcome/NN
./.
====================
Another/DT
developed/VBD
ribozyme/NN
that/DT
targets/VBZ
downstream/JJ
of/IN
the/DT
expanded/VBN
CUG/NN
repeats/NNS
(/(
Rib/NN
854/CD
)/)
could/MD
be/VB
useful/JJ
to/TO
replace/VB
the/DT
toxic/JJ
RNA/NN
that/DT
is/VBZ
entrapped/VBN
in/IN
the/DT
nucleus/NN
with/IN
RNA/NN
that/DT
can/MD
be/VB
released/VBN
into/IN
the/DT
cytoplasm/NN
./.
====================
Recent/JJ
findings/NNS
showed/VBD
that/IN
mDMPK/NN
3/CD
’/NNP
UTR/NN
that/IN
is/VBZ
aberrantly/RB
retained/VBN
in/IN
the/DT
nucleus/NN
could/MD
be/VB
transported/VBN
extensively/RB
to/TO
the/DT
cytoplasm/NN
when/WRB
it/PRP
has/VBZ
attached/VBN
to/TO
its/PRP$
3/CD
’/NNP
end/NN
the/DT
woodchuck/NN
post/RB
transcriptional/JJ
regulatory/JJ
element/NN
(/(
WPRE/NNP
)/)
,/,
which/WDT
can/MD
naturally/RB
accumulate/VBP
hepatitis/NN
transcripts/NNS
in/IN
the/DT
cytoplasm/NN
,/,
resulting/VBG
in/IN
an/DT
increase/NN
in/IN
myoblast/JJ
differentiation/NN
whose/WP$
initiation/NN
is/VBZ
failed/VBN
in/IN
mutant/JJ
3/CD
’/NNP
UTRexpressing/VBG
cells/NNS
(/(
Mastroyiannopoulos/NNS
et/FW
al./FW
,/,
2005/CD
and/CC
2008/CD
)/)
./.
====================
Therefore/RB
,/,
RNA/NN
replacement/NN
of/IN
the/DT
mDMPK/NN
3/CD
’/NN
UTR/NN
RNA/NN
with/IN
RNA/NN
with/IN
WPRE/NN
could/MD
stimulate/VB
cytoplasmic/JJ
release/NN
of/IN
the/DT
mDMPK/NN
transcript/NN
,/,
relieving/VBG
the/DT
pathogenic/JJ
effects/NNS
that/IN
are/VBP
induced/VBN
by/IN
the/DT
toxic/JJ
RNA/NN
./.
====================
Another/DT
group/NN
also/RB
suggested/VBD
that/IN
the/DT
transsplicing/VBG
ribozyme/NN
approach/NN
may/MD
form/VB
a/DT
therapeutic/JJ
strategy/NN
for/IN
diseases/NNS
that/IN
are/VBP
associated/VBN
with/IN
repeat/NN
expansions/NNS
,/,
including/VBG
DM1/NN
(/(
Phylactou/NNP
et/FW
al./FW
,/,
1998/CD
)/)
./.
====================
However/RB
,/,
the/DT
authors/NNS
constructed/VBD
and/CC
characterized/VBN
a/DT
ribozyme/NN
that/DT
targeted/VBN
a/DT
randomized/JJ
selected/VBN
site/NN
./.
====================
An/DT
essential/JJ
factor/NN
that/WDT
influences/VBZ
the/DT
efficacy/NN
of/IN
RNAmediated/JJ
gene/NN
therapeutic/JJ
approaches/NNS
is/VBZ
the/DT
accessibility/NN
of/IN
inhibitory/JJ
elements/NNS
for/IN
binding/VBG
to/TO
the/DT
target/NN
RNA/NN
./.
====================
RNA/NN
mapping/VBG
studies/NNS
,/,
which/WDT
were/VBD
performed/VBN
in/IN
this/DT
study/NN
,/,
therefore/RB
,/,
should/MD
be/VB
preceded/VBN
to/TO
select/VB
the/DT
most/JJS
accessible/JJ
sites/NNS
in/IN
the/DT
target/NN
RNA/NN
,/,
develop/VBP
the/DT
most/JJS
potent/JJ
RNA/NN
inhibitors/NNS
,/,
and/CC
optimize/VBP
intracellular/JJ
antimDMPK/JJ
RNA/NN
activity/NN
./.
====================
Noticeably/RB
,/,
this/DT
study/NN
showed/VBD
that/IN
very/RB
stable/JJ
RNAs/NNS
,/,
such/JJ
as/IN
mDMPK/NN
3/CD
’/NN
UTR/NN
,/,
were/VBD
successfully/RB
targeted/VBN
and/CC
mapped/VBD
with/IN
the/DT
transsplicing/VBG
ribozyme/NN
./.
====================
The/DT
mapping/NN
procedure/NN
that/DT
was/VBD
performed/VBN
in/IN
this/DT
study/NN
could/MD
be/VB
broadly/RB
useful/JJ
for/IN
the/DT
identification/NN
of/IN
the/DT
most/JJS
accessible/JJ
sites/NNS
in/IN
specific/JJ
diseaseassociated/JJ
transcripts/NNS
to/TO
develop/VB
therapeutic/JJ
strategies/NNS
with/IN
RNA/NN
in/IN
hibitors/NNS
./.
====================
